Immune cells found near tumours boost breast cancer survival

June 10, 2014

Women with breast cancer are 10 per cent more likely to survive for five years or more if they have certain immune cells near their tumour, according to research published in Annals of Oncology today.

The researchers looked for an immune cell called a killer T cell which specialises in destroying rogue cells in the body, such as .

The Cancer Research UK study found that when these immune cells were present, survival improved for women with ER-negative and ER-positive HER2-postive . However, survival didn't change for women with ER-positive HER2-negative breast cancer.

Study author, Dr Raza Ali, National Institute for Health Research clinical lecturer at the Cancer Research UK Cambridge Institute, University of Cambridge, said: "Cancer often finds ways to escape the , but helping to recognise cancer as a threat - and attack it - provides a promising and powerful avenue for new treatments. We've shown that women who have killer T cells present at the site of their tumour are likely to live longer.

"This important insight could help doctors personalise a woman's treatment based on her immunological profile and also suggests that new treatments should harness the immune system to fight cancer."

Immune cells were counted and analysed from samples collected from 12,439 from four different studies across England and Canada.

The research shows that infiltration into the tumour by killer T cells flags up how certain patients should be treated. The finding also suggests that chemotherapy could be given alongside immunotherapy drugs. Chemotherapy treatment such as doxorubicin in particular may be enhanced when killer T cells are present.

Professor Carlos Caldas, senior group leader at the Cancer Research UK Cambridge Institute, University of Cambridge, said: "The more we learn about how precisely the immune system interacts with breast cancer the better we are able to fine tune the treatments we give to patients - and the sooner we can save more lives.

"This was the largest ever study of its type looking at data from over 12,000 patients. Crucial research such as this is only possible due to the collaboration available at the Cambridge Cancer Centre, a partnership between Cancer Research UK, the University of Cambridge and Addenbrooke's Hospital."

Professor Peter Johnson, Cancer Research UK's chief clinician, said: "This research highlights the great strides we are making in understanding the complex interplay between cancer and the body's immune system. These studies are key to informing how we are best able to treat in the clinic and to design better drugs that make the best use of the body's own defences."

Explore further: Combining imaging and gene analysis could transform breast cancer diagnosis

More information: Ali HR, Provenzano E, Dawson SJ et al. "Association between CD8+ T-cell infiltration and breast cancer survival in 12439 patients." Ann Oncol 2014. DOI: 10.1093/annonc/mdu191

Related Stories

Redirecting our immune cells to help fight children's cancer

November 6, 2013

Immune cells, known as Natural Killer T cells, could be redirected to help fight the childhood cancer, neuroblastoma, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool ...

Recommended for you

Combination therapy can prevent cytostatic resistance

November 26, 2015

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

Forecasting the path of breast cancer in a patient

November 23, 2015

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.